Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Roberto Iacovelli(Agostino Gemelli University Polyclinic), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo Maria Deppieri(Istituto Oncologico Veneto), Chiara Ciccarese(Agostino Gemelli University Polyclinic), Luca Galli(University of Pisa), Marco Maruzzo(Istituto Oncologico Veneto), Antonella Cannella(Agostino Gemelli University Polyclinic), Giampaolo Tortora(University of Naples Federico II), Elena Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Sergio Bracarda(Azienda Ospedaliera S.Maria), Francesco Massari(Altera (United States)), Claudia Caserta(Inserm), Federico Paolieri(Azienda Ospedaliera Universitaria Pisana), Francesco Atzori(Azienda Ospedaliero-Universitaria Cagliari), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Sarah Scagliarini(Ospedale Antonio Cardarelli), Mariele Dessì(Azienda Ospedaliero-Universitaria Cagliari), Maria Grazia Maratta(Agostino Gemelli University Polyclinic), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Umberto Basso(Istituto Oncologico Veneto), Davide Bimbatti(Istituto Oncologico Veneto)
Cited by 9
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k